Tsanyang JakeLiangMD

Gastroenterology • Bethesda, MD

Hepatology & Liver Transplantation

NIH Distinguished Investigator, Chief of Liver Diseases Branch, Deputy Director of Translational Research, NIDDK, NIH

Join to view full profile

Dr. Liang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Liang's full profile

Already have an account?

Office
Ldb Niddk Nih Bldg 10-9b16
10 Center Drive
Bethesda, MD 20892
Phone+1 301-496-1721
Is this information wrong?

Education & Training

Massachusetts General HospitalFellowship, Gastroenterology, 1987 - 1991
NYU Grossman School of MedicineResidency, Internal Medicine, 1985 - 1987
Harvard Medical SchoolClass of 1984

Certifications & Licensure

MA State Medical License 1987 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Gastroenterology

Awards, Honors, & Recognition

Elected Member American Academy of Microbiology, 2017
Elected Member National Academy of Medicine, The National Academies of Sciences, Engineering and Medicine, 2016
Elected Member Association of American Physicians, 2002
Elected Member The American Society for Clinical Investigation, 1996
Join now to see all

Publications & Presentations

PubMed

5 citations
Virology: The X-Files of hepatitis B
T. Jake Liang> ;Nature. 2016 Mar 17
62 citations
Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable.
Anna S.F. Lok, John W. Ward, Robert P. Perrillo, Brian J. McMahon, T. Jake Liang> ;Annals of Internal Medicine. 2012 May 15
Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial.
Ghany MG, Kim HY, Stoddard A, Wright EC, Seeff LB, Lok AS, HALT-C Trial Group> ;Hepatology (Baltimore, Md.).
Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C.
Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR, HALT-C Trial Group> ;Hepatology (Baltimore, Md.).
Hepatitis C pharmacogenetics: state of the art in 2010.
Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, Murray JS, Shianna KV, Tanaka Y, Thomas DL, Booth DR, Goldstein DB, Pharmacogenetics and Hepatitis C Meeti...> ;Hepatology (Baltimore, Md.).
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C.
Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, Lee WM, Lok AS, Di Bisceglie AM, Bonkovsky HL, Hoefs JC, Dienstag JL, Morishima C, Abnet CC, Sin...> ;Hepatology (Baltimore, Md.).
Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepa...
Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer RM, Wright EC, Hutchinson AA, Crenshaw AT, Bashirova A, Carrington M, Dotrang M, Sterling RK, Lindsay KL, Fo...> ;Hepatology (Baltimore, Md.).
Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.
Lok AS, Everhart JE, Chung RT, Kim HY, Everson GT, Hoefs JC, Greenson JK, Sterling RK, Lindsay KL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Ghany MG, Morishima C, HALT-C...> ;Hepatology (Baltimore, Md.).
Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection.
Hoofnagle JH, Wahed AS, Brown RS, Howell CD, Belle SH, Virahep-C Study Group> ;The Journal of infectious diseases.
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.
Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL, HAL...> ;The New England journal of medicine.
53 citations
Hepatitis C: a clinical review.
AA Modi, TJ Liang> ;Oral Diseases. 2007 Dec 18
65 citations
Development of a plant-derived subunit vaccine candidate against hepatitis C virus.
L. G. Nemchinov, T. J. Liang, M. M. Rifaat, H. M. Mazyad, Ahmed Hadidi, J. M. Keith> ;Archives of Virology. 2000 Jan 1
256 citations
Infusion of α-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease
Raphael Schiffmann, Gary J. Murray, Douglas A. Treco, Peter Francis Daniel, M. Sellos-Moura, M. Myers, Jane M. Quirk, Gregory C. Zirzow, Marianne Borowski, Kenneth S. ...> ;Proceedings of the National Academy of Sciences of the United States of America. 2000 Jan 4
157 citations
Two core promotor mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication.
Thomas F. Baumert, S A Rogers, K. Hasegawa, T J Liang> ;The Journal of Clinical Investigation. 1996 Nov 15
85 citations
Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors.
T J Liang, A E Reid, Ramnik J. Xavier, Robert D. Cardiff, Timothy C. Wang> ;The Journal of Clinical Investigation. 1996 Jun 15
14 citations
Molecular cloning of two types of cDNA encoding subunit RC6-I of rat proteasomes.
Runzhou Ni, Yumiko Tomita, Fuminori Tokunaga, T. Jake Liang, Chiseko Noda, Akira Ichihara, Keiji Tanaka> ;Biochimica Et Biophysica Acta. 1995 Oct 17
4 citations
Association of hepatitis C virus and hepatocellular carcinoma in the United States.
A E Reid, T J Liang> ;Princess Takamatsu Symposia. 1995 Jan 1
35 citations
Presence of hepatitis B and C viral genomes in US blood donors as detected by polymerase chain reaction amplification
T. J. Liang, H. C. Bodenheimer, R. Yankee, Nancy V. Brown, K. Chang, Jiakang Huang, Jack R. Wands> ;Journal of Medical Virology. 1994 Feb 1
66 citations
Hepatitis B virus precore mutation and fulminant hepatitis in the United States. A polymerase chain reaction-based assay for the detection of specific mutation.
T J Liang, K. Hasegawa, S. J. Munoz, Craig N. Shapiro, Boris Yoffe, Brian J. McMahon, Chengyin Feng, Hucheng Bei, M. J. Alter, Jules L. Dienstag> ;The Journal of Clinical Investigation. 1994 Feb 1
128 citations
A novel hepatitis B virus (HBV) genetic element with Rev response element-like properties that is essential for expression of HBV gene products.
Jiakang Huang, T. J. Liang> ;Molecular and Cellular Biology. 1993 Dec 1
8 citations
HCV RNA in patients with chronic hepatitis C treated with interferon‐α
T. J. Liang, V. Rustgi, E. Galun, Hubert E. Blum> ;Journal of Medical Virology. 1993 May 1
23 citations
Targeted transfection and expression of hepatitis B viral DNA in human hepatoma cells.
T J Liang, W. J. Makdisi, S. Sun, K. Hasegawa, Ying Zhang, C. H. Wu, George Y. Wu, Jack R. Wands> ;The Journal of Clinical Investigation. 1993 Mar 1
54 citations
Carboxy-terminal-extended variant of the human fibrinogen alpha subunit: a novel exon conferring marked homology to beta and gamma subunits.
Yiping Fu, L. Weissbach, P. W. Plant, C. Oddoux, Yan Cao, T. J. Liang, Samar Roy, Colvin M. Redman, Gerd Grieninger> ;Biochemistry. 1992 Dec 8
21 citations
Molecular pathogenesis of liver disease during persistent hepatitis B virus infection.
Liang Tj, Blum He, Shafritz Da, Wands> ;Seminars in Liver Disease. 1992 Aug 1
61 citations
Association of hepatitis B viral precore mutations with fulminant hepatitis B in Japan
Kiyoshi Hasegawa, Jiakang Huang, Hiroshi Obata, T. Jake Liang, Jack R. Wands> ;Virology. 1991 Nov 1
Join now to see all

Journal Articles

Hepatitis B Virus Deregulates Cell Cycle to Promote Viral Replication and a Premalignant Phenotype
Tsanyang Jake Liang, MD, mBio